BREGAL-MILESTONE
Bregal Milestone, a leading European technology and software private equity firm and majority owner of Allshares, a pioneering compensation and long-term incentive software and services provider, today announced the acquisition of Novare Pay and the appointment of Michael Ingelög as Chair of the Allshares Board.
Novare Pay, based in Stockholm, is acclaimed for its reputation as a high-growth, high-margin European compensation services provider with a strong Nordic heritage. With an impressive clientele including leading multinational enterprises, Novare Pay's integration into the Allshares ecosystem will translate to an enhanced end-to-end digital turnkey offering to its over 630 clients spanning more than 40 countries worldwide. The acquisition of Novare Pay further fortifies Allshares' leadership position as one of Europe’s leading compensation software and services providers, with augmented and strengthened capabilities across compensation data and analytics, incentives, and governance. At closing, Novare Pay will rebrand and operate under the Allshares name.
Commenting on the landmark acquisition, Erika Andersson, CEO of Novare Pay, expressed her enthusiasm, stating, "Over the years, we have built a strong and diversified customer footprint and a talented team operating from our strategic hubs in Stockholm, Oslo, and London. Partnering with Allshares presents an exciting opportunity to not only enhance our service delivery with tech-forward compensation software but also to help spearhead a transformative shift in the European compensation landscape."
Cyrus Shey, Co-Founder and Managing Partner at Bregal Milestone, echoed Andersson's sentiments, saying, "We extend a warm welcome to Erika, Andreas, and the entire Novare Pay team as they join the Allshares family. Leveraging Novare Pay's specialized expertise in pay, remuneration, and compensation, alongside its client-centric approach, this partnership will help propel Allshares to new heights across Europe, re-affirming their steadfast commitment to delivering leading compensation solutions that drive high performance for both private and publicly listed customers. With Michael's appointment as Chair, we are confident in our ability to harness this momentum and further strengthen Allshares’ position as an industry leader."
As Chairman Michael Ingelög brings his wealth of experience as a seasoned CEO and board executive with deep knowledge of the Nordic and European markets. In response to his appointment and the acquisition of Novare Pay to the Allshares family, Ingelög commented, “Allshares’ distinctive solutions built and delivered by industry experts underpinned my decision to join as Chair of the Board. With the recent addition of Novare Pay to the Allshares family, Allshares is poised to enhance its offerings even further and truly transform the European compensation landscape. I'm thrilled to help shape the company’s future, alongside management and the board.”
The terms of the transaction were not disclosed and are subject to customary closing conditions.
About Bregal Milestone
Bregal Milestone is a leading European software and technology private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading technology companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €18 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2023. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.
About Allshares
Allshares is a market leader for equity plan design and administration in the Nordics. Trusted by leading multinational enterprises, Allshares serves approximately 300 multinational public and private enterprise customers in more than 100 countries with an end-to-end digital turnkey solution for equity plan management. Companies and participants can use its proprietary software and services to administer share plans in full compliance with relevant regulations, legal, and tax frameworks, as well as deliver seamless and automated IFRS reporting of share plans to companies. For more information, visit www.allshares.com
About Novare Pay
Novare Pay is a premier provider of remuneration services to multinationals. With a dedicated team of over 50 seasoned specialists stationed across Stockholm, Oslo, and London, Novare Pay offers bespoke compensation services and analytics tailored to clients' needs. Novare Pay boasts an impressive track record of high-growth, high-margin fundamentals, while serving over 900 clients in more than 60 countries. For more information, visit www.allshares.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240512957761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom